|
gptkbp:instanceOf
|
gptkb:drug
nitrofuran
|
|
gptkbp:administeredBy
|
gptkb:eflornithine
gptkb:benznidazole
|
|
gptkbp:approvedBy
|
gptkb:Europe
gptkb:Latin_America
gptkb:United_States
1960s
|
|
gptkbp:ATCCode
|
P01CC02
|
|
gptkbp:brand
|
gptkb:Lampit
|
|
gptkbp:CASNumber
|
23256-30-6
|
|
gptkbp:chemicalFormula
|
C9H13N3O5S
|
|
gptkbp:contraindication
|
neurological disorders
severe kidney disease
severe liver disease
|
|
gptkbp:discoveredBy
|
gptkb:Bayer
|
|
gptkbp:drugClass
|
antiprotozoal
|
|
gptkbp:eliminationHalfLife
|
3 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
nifurtimox
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
produces reactive oxygen species toxic to parasites
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
287.29 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
not recommended in pregnancy
|
|
gptkbp:prescribes
|
adults
children
infants
immunocompromised patients
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
abdominal pain
headache
weight loss
peripheral neuropathy
|
|
gptkbp:synonym
|
gptkb:Bayer_2502
gptkb:Nifurtimoxum
gptkb:Nifurtimoxum_(INN)
|
|
gptkbp:UNII
|
8U9T5I6877
|
|
gptkbp:usedFor
|
gptkb:African_trypanosomiasis
gptkb:Chagas_disease
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:African_trypanosomiasis
gptkb:American_trypanosomiasis
gptkb:Trypanosoma_cruzi
gptkb:Chagas_disease
gptkb:Trypanosoma
|
|
gptkbp:bfsLayer
|
6
|